DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.56%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$362M
AUM Growth
+$362M
(+2.7%)
Cap. Flow
-$9.38M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$2.11M |
| 2 |
Compass Therapeutics
CMPX
|
$1.37M |
| 3 |
Inogen
INGN
|
$1.04M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$975K |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$961K |
Top Sells
| 1 |
Merus
MRUS
|
$3.31M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.05M |
| 3 |
TSVT
2seventy bio
TSVT
|
$2.12M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$1.93M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Cardiff Oncology
CRDF
$130M
| – | – |
-150,000
| Closed | -$471K |
|
77
Lineage Cell Therapeutics
LCTX
$279M
| – | – |
-2,511,374
| Closed | -$1.13M |
|
|
RGLS
78
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-847,176
| Closed | -$1.48M |
|
|
SAGE
79
DELISTED
Sage Therapeutics
SAGE
| – | – |
-108,200
| Closed | -$860K |
|
80
Spero Therapeutics
SPRO
$115M
| – | – |
-125,000
| Closed | -$90K |
|
81
ARS Pharmaceuticals
SPRY
$1.1B
| – | – |
-95,290
| Closed | -$1.2M |
|
82
Tenaya Therapeutics
TNYA
$176M
| – | – |
-47,319
| Closed | -$27K |
|
83
Taysha Gene Therapies
TSHA
$797M
| – | – |
-522,500
| Closed | -$726K |
|
|
TSVT
84
DELISTED
2seventy bio
TSVT
| – | – |
-429,252
| Closed | -$2.12M |
|
|
NVRO
85
DELISTED
NEVRO CORP.
NVRO
| – | – |
-38,000
| Closed | -$222K |
|